Table 2.
Antimicrobial resistance profile of blaCTX-M-IV-harboring K. pneumoniae clinical isolates and their transformants.
| K. pneumoniae Isolates | Cefotaxime MIC (μg/mL) |
Fold Increase in Cefotaxime MIC a |
Resistance Profile b |
|---|---|---|---|
| K7 | 1024 | - | AMC, CAZ, IPM, CTX, FEP, DO, GEN, CIP |
| Transformant of K7 | 8 | 64 | AMC, CAZ, CTX |
| K14 | 1024 | - | AMC, CAZ, IPM, CTX, SXT, FEP, GEN, CIP |
| Transformant of K14 | 16 | 128 | AMC, CAZ, CTX |
| K23 | 1024 | - | AMC, CAZ, IPM, CTX, SXT, FEP, DO, GEN, CIP |
| Transformant of K23 | 4 | 32 | AMC, CAZ, CTX |
a The recipient, E. coli DH5α, was cefotaxime sensitive with an MIC of 0.125 μg/mL. b AMC, amoxicillin/clavulanate; CAZ, ceftazidime; IPM, imipenem; CTX, cefotaxime; SXT, sulfamethoxazole/trimethoprim; FEP, cefepime; DO, doxycycline; CIP, ciprofloxacin; GEN, gentamicin. Antibiotics to which the tested isolates showed intermediate resistance are in bold format.